Factsheet helping vaccine-hesitant patients understand Novavax is based on different technologies

SWSPHN has identified that people from some vulnerable groups may be vaccine averse due to the association between mRNA COVID vaccines and foetal cells.

In response, we have created an information sheet about Novavax to address this barrier.

It is available in English and the languages of our high-risk, low-vaccinated groups.

The Chaldean, Assyrian, and Arabic groups have lower than 25 per cent third dose vaccination coverage which increases their risk of COVID-related complications.

If you know of people who are vaccine adverse, particularly those in the identified groups above, please share with them this information about how Novavax is different.